FDA Reviews Samsung Bioepis’ Bevacizumab
Avastin Rival Will Be Sold Through Merck, Sharp & Dohme
Executive Summary
Samsung Bioepis has announced that its SB8 biosimilar bevacizumab candidate, a proposed US rival to Avastin, has been accepted for review by the FDA.
You may also be interested in...
Amneal Takes A Step Forward On Biosimilars
The FDA’s acceptance of Amneal’s filing for bevacizumab brings the company a step closer to its goal of launching a US biosimilar every year to 2023.
Merck & Co Puts A Date On Spinning Off Biosimilars
Merck & Co has disclosed more precise details around plans to spin off its more mature products, including biosimilars, into a new publicly traded company.
Bio-Thera Follows EU Bevacizumab Biosimilar Filing With FDA Goal Date
China’s Bio-Thera is continuing its journey to bring biosimilars to patients across the globe, with its BAT1706 biosimilar bevacizumab candidate accepted for filing by the US Food and Drug Administration.